secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aprea Therapeutics, Inc. (APRE)
CIK:        0001781983
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001558370-24-014768
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aprea Therapeutics Reports Q3 2024 Financial Results; Cash $26.2M, Net Loss $3.8M
--------------------------------------------------------------------------------

- Cash and cash equivalents of $26.2 million as of Sept 30, 2024, providing at least twelve months of runway.
- Operating loss of $4.1 million for Q3 2024 versus $3.5 million in Q3 2023; net loss of $3.8 million ($0.64 per share).
- Phase 1 ACESOT-1051 trial of WEE1 inhibitor APR-1051 shows well-tolerated profile with no unexpected toxicities at subtherapeutic doses.
- Phase 1/2a ABOYA-119 trial of ATR inhibitor ATRN-119 enrolling at dose level 6 (800 mg QD); twice-daily dosing added to protocol.
- Engaged Philippe Pultar, MD as senior medical advisor in October 2024 to support APR-1051 development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781983/000155837024014768/0001558370-24-014768-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781983/000155837024014768/apre-20241107x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-014768

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer